Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel

Journal of Clinical Oncology

Volumn 19, Issue 4, 2001, Pages 1160-1166

  Malingre M M ^a   Richel, D J ^a   Beijnen, J H ^a   Rosing, H ^a   Koopman, F J ^a   Ten Bokkel Huinink W W, ^a   Schot, M E ^a   Schellens, J H M ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450 3A4; DOCETAXEL; GLYCOPROTEIN P;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR;

EID: 0035865162     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.4.1160     Document Type: Article

References (26)

1. Oral chemotherapy: Rationale and future directions
2. Patient preferences for oral versus intravenous palliative chemotherapy
3. Limited oral bioavailability and active epithelial secretion of paclitaxel caused by P-glycoprotein in the intestine
4. Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers
5. Clinical pharmacology and metabolism of Taxol (paclitaxel): Update
6. Hepatic biotransformation of docetaxel (Taxotere) in vitro: Involvement of the CYP3A subfamily in humans
7. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of Taxotere and its derivatives: Enzyme specificity, interindividual distribution and metabolic contribution in human liver
8. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A
9. Co-administration of cyclosporin enables oral therapy with paclitaxel
10. Coadministration of cyclosporin A enables oral therapy with paclitaxel
11. Enhanced oral bioavailability of paclitaxel in mice co-treated with the P-glycoprotein blocker SDZ PSC 833
12. Bio-analysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction
13. Relative performance of specific and nonspecific fluorescence immunoassay for cyclosporin in transplant patients
14. Noncompartmental analysis based on statistical moment theory
15. Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion
16. Cyclosporin metabolism in transplant patients
17. Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450111A
18. Isolation, purification and biological activity of major docetaxel metabolites from human feces
19. The physiological function of drug-transporting P-glycoproteins
20. Disruption of the mouse mdrla P-glycoprotein gene leads to deficiency in the blood-brain barrier and to increased sensitivity to drugs
21. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer
22. Activity of weekly Taxotere (TXT) in patients with metastatic breast cancer
23. Weekly docelaxel in patients with advanced malignancies: Toxicity profile and activity results
24. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors